Evidence map›Paper›PMID 38247539›Full record

ArticleAntioxidants (Basel, Switzerland)2024

PKCiota Inhibits the Ferroptosis of Esophageal Cancer Cells via Suppressing USP14-Mediated Autophagic Degradation of GPX4.

Hao Tao, Sheng-Jie Song, Ze-Wen Fan, Wen-Ting Li, Xin Jin, Wen Jiang, Jie Bai, Zhi-Zhou Shi

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. [Ferroptosis suppressor genes are highly expressed in esophageal cancer to inhibit tumor cell ferroptosis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hao TaoMedical School, Kunming University of Science and Technology, Kunming 650500, China.
Sheng-Jie SongMedical School, Kunming University of Science and Technology, Kunming 650500, China.
Ze-Wen FanMedical School, Kunming University of Science and Technology, Kunming 650500, China.
Wen-Ting LiMedical School, Kunming University of Science and Technology, Kunming 650500, China.
Xin JinMedical School, Kunming University of Science and Technology, Kunming 650500, China.
Wen JiangDepartment of Thoracic Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650000, China.
Jie BaiMedical School, Kunming University of Science and Technology, Kunming 650500, China.
Zhi-Zhou ShiMedical School, Kunming University of Science and Technology, Kunming 650500, China.
Kunming University of Science and Technology · CNFirst People's Hospital of Yunnan Province · CN

Funding

Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences 2021-I2M-1-018Joint Medical Program of Kunming University of Science and Technology KUST-KH2022001Z and KUST-PE2022002ZNational Natural Science Foundation of China 82160585The innovation team of oxidative stress and defense of Yunnan Province 202305AS350011Yunnan (Kunming) Zhou Demin Expert Workstation Project YSZJGZZ-2020046
6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most frequent malignant tumors, and the mechanisms underlying the anti-ferroptosis of esophageal cancer cells are still largely unclear. This study aims to explore the roles of amplified protein kinase C iota (PKCiota) in the ferroptosis of ESCC cells. Cell viability, colony formation, MDA assay, Western blotting, co-IP, PLA, and RNA-seq technologies are used to reveal the roles and mechanisms underlying the PKCiota-induced resistance of ESCC cells to ferroptosis. We showed here that PKCiota was amplified and overexpressed in ESCC and decreased during RSL3-induced ferroptosis of ESCC cells. PKCiota interacted with GPX4 and the deubiquitinase USP14 and improved the protein stability of GPX4 by suppressing the USP14-mediated autophagy-lysosomal degradation pathway. PKCiota was negatively regulated by miR-145-5p, which decreased in esophageal cancer, and also regulated by USP14 and GPX4 by a positive feedback loop. PKCiota silencing and miR-145-5p overexpression suppressed tumor growth of ESCC cells in vivo, respectively; even a combination of silencing PKCiota and RSL3 treatment showed more vital suppressive roles on tumor growth than silencing PKCiota alone. Both PKCiota silencing and miR-145-5p overexpression sensitized ESCC cells to RSL3-induced ferroptosis. These results unveiled that amplified and overexpressed PKCiota induced the resistance of ESCC cells to ferroptosis by suppressing the USP14-mediated autophagic degradation of GPX4. Patients with PKCiota/USP14/GPX4 pathway activation might be sensitive to GPX4-targeted ferroptosis-based therapy.

Indexed as

esophageal squamous cell carcinomaferroptosisGPX4PKCiotaUSP14

Identifiers

PMID38247539
PMCPMC10812620
OpenAlexW4390944369

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.